Isotopia Co. and Bar-Ilan U. developing new method for diagnosis and treatment of cancer
Share

The Israeli Isotopia Company, in collaboration with Prof. Rachela Popovtzer of Bar-Ilan University, is conducting a joint study to develop a radioactive marker, based on nanoparticles, for the detection of cancer. The goal of this research is to facilitate, for the first time, the distinction between tumors and inflammation.

The most common imaging method for diagnosing and monitoring cancer today is the positron emission tomography (PET) scan used with radioactive contrast material fluorodeoxyglucose (FDG). However, FDG gives high rates of false positives, which lead to false therapeutic observations and expensive costs for health care systems. The main problem is that the test can detect not only tumors, but also inflammation, making it difficult to differentiate between cancerous growths and inflammation.

The material being developed by the researchers is a radioactive contrast agent based on nanoparticles. In addition to identifying, imaging and tracking cancer tumors, these nanoparticles make it possible to make an unequivocal distinction between tumor and inflammation.

“The technology we are developing is significant because it will enable physicians to make a better diagnosis,” said Dr. Eli Shalom, CEO of Isotopia Molecular Imaging. “Another advantage is that it will be used in existing PET/CT centers and rely on

read more...


Article originally posted at
www.eurekalert.org

Click here for the full story


CategoryAggregator News

© 2017 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

Powered by MMD